Betamimetics Synthesis for Extended Duration Action
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current betamimetic drugs for treating COPD and asthma have a short duration of action, requiring frequent administration and lacking selectivity for β2-adrenoceptors, which complicates patient compliance and therapeutic efficacy.
Innovation Solution
A process for preparing betamimetics with a longer duration of action by reacting specific compounds in organic solvents, using protecting groups and catalysts to enhance selectivity and potency, allowing for once-daily administration.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If conventional betamimetic drugs are used for treating COPD and asthma, then therapeutic effect is achieved, but duration of action is short requiring frequent administration
Solution Approach 1:
The patent modifies the chemical structure of betamimetic compounds by changing parameters such as introducing specific substituents (e.g., at positions 6, 8, or 9 of the core structure) and adjusting molecular weight and lipophilicity to extend the duration of action. This allows once-daily administration while maintaining therapeutic efficacy.
2Reliability
If conventional betamimetic drugs are used, then therapeutic effect is achieved, but selectivity for β2-adrenoceptors is insufficient
Solution Approach 1:
The patent introduces specific functional groups and substituents at particular positions (6, 8, or 9) of the betamimetic core structure to enhance local binding affinity and selectivity for β2-adrenoceptors. This localized modification increases receptor specificity and reduces off-target effects at other adrenergic receptors.
3Reliability
If frequent administration is required, then therapeutic effect is maintained, but patient compliance is reduced
Solution Approach 1:
The patent extends the duration of action through dynamic modifications of the molecular structure, including introducing prodrugs that release active metabolites slowly over time. This dynamic release profile maintains therapeutic levels throughout the day, enabling once-daily dosing and improving patient compliance.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process results in betamimetics with extended therapeutic effects, improved selectivity for β2-adrenoceptors, and the ability to be administered once daily, enhancing patient compliance and treatment efficacy for COPD and asthma.
Implementation Method 1
a compound of formula 1a reacted in a suitable solvent with a compound of formula 1b
Implementation Method 2
The cleavage of the protecting group PG from compounds of formula 1a preferably takes place by means of hydrogenation in a suitable solvent
Data Source
AI summary
The invention relates to a method for producing betamimetics of formula (I), in which n represents 1 or 2; R1 represents hydrogen, halogen, C1-4 alkyl or O-C1-4 alkyl; R2 represents hydrogen, halogen, C1-4 alkyl or O-C1-4 alkyl, and; R3 represents hydrogen, C1-4 alkyl, OH, halogen, O-C1-4 alkyl, O-C1-4 alkylene-COOH, O-C1-4 alkylene-COO-C1-4-alkyl.